Compare Huntington Bancshares Incorporated (HBAN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Incyte Corporation — how do they compare? Huntington Bancshares Incorporated trades at $15.32 (market cap $31.04B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Huntington Bancshares Incorporated is the larger of the two by market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Incyte Corporation for 33 Days on average.
| HBAN | INCY | |
|---|---|---|
Market Cap | $31.04B | $22.85B |
Volume | 23,864,172 | 1,927,029 |
Sector | Financials | Health |
52-Week High | $19.27 | $129.93 |
52-Week Low | $15.02 | $83.80 |
Typical Hold Time | 52 Days | 33 Days |
Enterprise Value | $49.57B | $18.35B |
Dividend Yield | 4.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.32, up 0.99% on the day, with a bearish technical signal and mixed earnings history. The company reported 2025 revenue of $8.13B and net income of $2.21B, with a P/E of 11.82 and ROE of 9.23%. Recent news highlights an increased prime rate to 7.00% and a revised 2027 earnings outlook due to margin pressures.
Outlook is cautious; analyst consensus is a Buy with a $19.60 price target, but near-term headwinds from higher interest rates and deposit costs pose risks. The stock offers value based on valuation metrics, yet investors should weigh margin pressures against shareholder return initiatives like the $550M buyback plan for 2026.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
